Depression Diagnosis

Pioneering a New Era in Depression Diagnosis: Overcoming Skepticism with Science   Depression affects millions of people worldwide, yet its diagnosis remains largely subjective. Currently, most psychiatrists rely on depression rating scales—questionnaires that assess symptoms based on patient responses. While these tools are widely used, they leave room for interpretation and may not always capture the full biological complexity of depression.    Our company is changing that. We manufacture an in vitro diagnostic (IVD) product for depression—a groundbreaking innovation that provides an objective, Circular RNA biomarker-based approach to diagnosis. Despite the strong scientific backing of our products—supported by over 15 published research articles and more than 1,000 clinical trials—introducing this innovation to the market has been met with hesitation.    Facing Doubts in a Traditional Field When promoting our IVD products to hospitals, clinics, and distributors, the response is often cautious. Many medical professionals, accustomed to decades of subjective assessment tools, question the validity and necessity of a biological test for depression. Some common objections include:    Why do we need a diagnostic test when rating scales have worked for years? How do we know these biomarkers are reliable? Will insurance cover this? Will doctors adopt it?   These concerns are understandable. Change is difficult, especially in a field as complex as mental health. However, the resistance does not diminish the potential impact of our technology.    Standing Firm in Our Mission  Despite the skepticism, I remain unwavering in my commitment to bringing this innovation to the world. Every objection is an opportunity to educate—to demonstrate how our test can:  ✔ Improve diagnostic accuracy–Reducing misdiagnosis and ensuring patients receive the right treatment sooner.  ✔ Complement existing methods –Providing psychiatrists with additional data to make more informed decisions.  ✔ Reduce stigma – Reinforcing that depression is not just "in the mind" but has measurable biological components.    The Road Ahead Innovation is never easy. The greatest medical breakthroughs—from the discovery of antibiotics to the development of vaccines—faced initial resistance before becoming standard practice. Our journey is no different.  I will continue to engage with doctors, researchers, and healthcare providers, armed with data and real-world evidence. I will listen to their concerns, refine our approach, and persist in demonstrating the value of our IVD products.  Because at the heart of this mission are the millions of people suffering from depression—people who deserve faster, more accurate diagnoses and better treatment options. This is more than just a product. It’s a revolution in mental health care. And I won’t stop until the world sees its potential. 

The recognition, diagnosis, and differential diagnosis of depression vary across different ages, genders, cultural backgrounds, and disease states, and there is a lack of specific diagnostic methods. Comprehensive collection of objective and reliable historical data, along with meticulous psychological and physiological examinations, forms the foundation for accurate diagnosis. Nanjing Healed Gene Biotechnology Co., Ltd. provides scientific, standardized, and practical diagnostic and treatment guidance for primary medical institutions, effectively enhancing the ability of primary care physicians to recognize and treat depression. The company has clarified the screening, diagnosis, treatment, and follow-up processes for depression, emphasizing a comprehensive treatment model that combines psychotherapy and medication, bringing hope to patients with depression. We focus on the detection and treatment of depression, and in the future, our business will concentrate on the broader field of brain science. Currently, we have developed technology platforms for fluorescence PCR, molecular fluorescence hybridization, and nucleic acid drugs using blood and saliva samples. These platforms enable the creation of composite rapid detection kits for the quick and accurate quantitative diagnosis and risk assessment of depression, providing objective biological indicators for depression diagnosis. These kits can be applied in various settings, including hospital diagnostics, external physical examinations, and public self-testing. Nanjing Healed Gene Biotechnology Co., Ltd. uses fluorescence PCR technology to detect the levels of four circular RNA (circRNA) biomarkers in human plasma samples in vitro. The detection results, combined with clinical standard diagnostic methods, can be used for the clinical auxiliary diagnosis of depression. With advancements in technology and increased attention to mental health, the diagnosis and treatment of depression will become more precise, efficient, and humane. Guided by clinical standard diagnostic methods for circular RNA (circRNA) and the efforts of biotech companies like Nanjing Healed Gene Biotechnology Co., Ltd., more and more patients with depression will receive timely and effective treatment, regaining their health and happiness. Circular RNA: Pioneering a New Era of Precision Diagnosis and Treatment for Mental Disorders, Safeguarding a Happy and Fulfilling Life!